Company profile
HUMACYTE, INC.
NASDAQ:HUMABiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| SYMVESS | approved | $0.1MQ2 2025 | 0 | — |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (11)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07762313 | phase3 | not_yet_recruiting | 2026-09-01 | 2028-12-01 | Humacyte, Inc. | An Open-label Study to Assess the Safety and Efficacy of SYMVESS® as a Vascular Conduit in Adolescents With Extremity Arterial Injury. |
| NCT03183245 | phase3 | completed | 2017-09-29 | 2024-04-22 | Humacyte, Inc. | Comparison of the Human Acellular Vessel (HAV) With Fistulas as Conduits for Hemodialysis |
| NCT02644941 | phase3 | completed | 2016-05-24 | 2019-05-01 | Humacyte, Inc. | Comparison of the Human Acellular Vessel (HAV) With ePTFE Grafts as Conduits for Hemodialysis |
| NCT01872208 | — | completed | 2013-10-10 | 2016-05-30 | Humacyte, Inc. | Evaluation of the Safety and Efficacy of a Vascular Prosthesis as an Above-Knee Bypass Graft in Patients With PAD |
| NCT03005418 | phase2_3 | completed | 2018-09-01 | 2023-09-19 | Humacyte, Inc. | Humacyte Acellular Tissue Engineered Vessel (ATEV) in Patients With Vascular Trauma |
FDA applications (1)
| Application | Approved | Type | Applicant | Products | ||||
|---|---|---|---|---|---|---|---|---|
| BLA 125812 | 2024-12-19 | BLA | HUMACYTE GLOBAL INC. | |||||
Loading… | ||||||||